Maximum Dose of Dexilant
The maximum recommended dose of Dexilant (dexlansoprazole) for adults is 60 mg once daily. 1
FDA-Approved Dosing Parameters
Standard maximum dose: The FDA label explicitly states that dexlansoprazole is available in 30 mg and 60 mg capsule formulations, with 60 mg representing the highest approved single dose 1
Dosing frequency: Dexlansoprazole is administered once daily; there is no FDA-approved twice-daily regimen for this medication 1
Alternative formulation: Two 30 mg orally disintegrating tablets (ODTs) can be used as an alternative to one 60 mg capsule, providing equivalent 24-hour intragastric pH control, though systemic exposure (AUC) is approximately 25% lower with the ODT formulation 2
Clinical Context and Efficacy
GERD treatment: The 60 mg once-daily dose has demonstrated superior acid suppression compared to other PPIs, maintaining intragastric pH above 4.0 for approximately 60% of the 24-hour period, with particular efficacy during the nighttime (>12-24 hours postdose) interval 3
Comparative effectiveness: Dexlansoprazole 60 mg provides significantly better heartburn-free days and nights compared to placebo, and shows improved symptom control for atypical GERD manifestations (cough, globus) compared to lansoprazole 30 mg 4, 5
H. pylori eradication: When used off-label for H. pylori eradication, dexlansoprazole 60 mg once daily combined with amoxicillin 1 g twice daily and clarithromycin 500 mg twice daily for 7 days achieves a 93.7% eradication rate 6
Important Caveats
No dose escalation beyond 60 mg: The FDA label does not support exceeding 60 mg daily; if symptom control is inadequate at the maximum dose, switching to an alternative therapeutic strategy is recommended rather than dose escalation 1
Pediatric dosing (ages 12-17): The maximum dose remains 60 mg once daily in adolescents, with pharmacokinetic studies showing that this dose provides 78-81% of the systemic exposure observed in adults 1
Hepatic impairment: In patients with moderate hepatic impairment (Child-Pugh Class B), systemic exposure is approximately doubled; however, the FDA label does not mandate dose reduction, though clinical judgment should guide dosing in this population 1
Administration timing: While dexlansoprazole's dual delayed-release formulation is designed to be less dependent on meal timing than other PPIs, optimal administration is 30-60 minutes before a meal for consistency with general PPI principles 7